Zhonghan Zhang

6PUBLICATIONS
4CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 17, 2021
Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China.

Zhonghan Zhang, Fan Luo, Jiaxin Cao

|Jun 09, 2020
Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer.

Zhonghan Zhang, Yang Zhang, Fan Luo

|Nov 09, 2019
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).

Zhonghan Zhang, Fan Luo, Yang Zhang

|Nov 16, 2018
Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.

Shen Zhao, Zhonghan Zhang, Yaxiong Zhang

|Jan 14, 2018
Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.

Zhonghan Zhang, Yaxiong Zhang, Gang Chen

|Nov 25, 2017
Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.

Shen Zhao, Fangfang Gao, Yaxiong Zhang

Pageof 1

Frequent Collaborators

2 joint publications

Li Zhang

2 joint publications

Shaodong Hong

1 joint publications

Gang Chen

1 joint publications

Wenfeng Fang